Amanda Cass, PharmD, BCPS, BCOP

Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.

Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.

Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.

Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.

Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.